The payment was completed pursuant to the terms of the amended license agreement with Amarin Neuroscience. MultiCell estimates MCT-125 could generate up to $3 billion in cumulative worldwide sales during the time it is under patent protection. Under the terms of the agreement, Amarin could receive up to $275 million in milestone payments and cumulative royalty payments.
MCT-125 targets fatigue associated with multiple sclerosis. About two million people worldwide are afflicted with multiple sclerosis, and approximately 70% of them report fatigue as the worst symptom of their disease.
In a phase II trial conducted in the UK by Amarin, MCT-125 (then known as LAX-202) demonstrated efficacy in significantly reducing the levels of fatigue, with few if any side effects, in all multiple sclerosis patient populations enrolled in the study including relapse-remitting, secondary progressive and primary progressive.